The European Respiratory Society (ERS) International Congress 2023

Acetazolamide helps to reduce the chances of altitude-related adverse health effects (ARAHE) in patients with chronic obstructive pulmonary disease (COPD) in a study reported at ERS.

Tacrolimus given once daily significantly reduced the 3-year incidence of chronic lung allograft dysfunction (CLAD) in lung transplant patients compared with standard immunosuppressant in the open label, multicentre, ScanCLAD trial presented at ERS 2023.

Treatment with dupilumab significantly improved lung function in children with moderate-to-severe type 2 asthma compared with placebo, according to two post hoc analyses presented at ERS 2023.

Use of e-cigarette (EC) shows a significant relation with a higher incidence of chronic stress and is indicative of poorer quality of life (QoL) in young adults, suggests a study presented at ERS 2023.

Fatigue in people with chronic obstructive pulmonary disease (COPD) may be caused by factors such as shortness of breath, sleep quality, pain, and fatigue-related catastrophizing, according to the FAntasTIGUE study.

A recent Mendelian randomization (MR) study provides genetic evidence showing that smoking can accelerate ageing as a result of shortened leucocyte telomere length (LTL). However, quitting may help reduce such risk.

Treatment with benralizumab significantly reduces the annual asthma exacerbation rate (AAER) among Asian patients with severe uncontrolled asthma compared with placebo, according to a subgroup analysis of the MIRACLE trial presented at ERS 2023.

Inhaled chlorpheniramine maleate appears to reduce the risk of prolonged post-COVID symptoms, according to a study presented at ERS Congress 2023.